![Regenxbio, Inc. [RGNX] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/Regenx_Bio_Inc_b1c83aa28b.png)
Regenxbio, Inc. [RGNX] Securities Class Action Lawsuit Update
REGENXBIO, Inc. (RGNX) Securities Class Action Lawsuit: Investors Allege Gene Therapy Safety Risks Were Concealed
![Enphase Energy, Inc. [ENPH] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/Enphase_ENPH_5dddd4cc43.png)
Enphase Energy, Inc. (ENPH) Securities Class Action Lawsuit: What Investors Allege and Why It Matters
Learn about securities lawsuits tied to your portfolio and recover money!
Enphase Energy, Inc. once positioned itself as a company that could manage volatility like policy shifts, inventory cycles, and demand fluctuations through discipline and control. Investors now allege that those assurances did not hold.
A federal securities class action filed in the Northern District of California accuses Enphase and two senior executives of misleading the market about channel inventory levels, revenue sustainability, and the company’s ability to offset the looming expiration of a key U.S. solar tax credit. When Enphase later disclosed elevated inventory, weaker forward guidance, and heavy reliance on “safe harbor” revenue, the stock dropped sharply, triggering the lawsuit and substantial investor losses.
“Most ENPH shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.
Enphase Energy, Inc. is a global energy technology company founded in 2006, focused on solar generation, battery storage, and energy communication systems. Its products are widely used in residential solar installations, both through direct sales and via third-party ownership arrangements.
A critical pillar of Enphase’s growth strategy involved partnerships with solar and battery financing companies (known as TPOs) which offer leases and power-purchase agreements to homeowners. These arrangements were particularly sensitive to U.S. tax incentives, including the Residential Clean Energy Credit under Internal Revenue Code Section 25D, which allowed homeowners to deduct 30% of qualifying clean-energy installation costs.
During the class period, Enphase repeatedly emphasized its ability to manage channel inventory and to adapt its business model ahead of the scheduled expiration of the 25D credit. Investors allege those claims masked growing operational strain.
Throughout 2025, Enphase executives publicly stressed control. On earnings calls, management described channel inventory as “normal” or only “slightly elevated,” insisting it remained within disciplined targets of roughly eight to ten weeks. The company also projected confidence in new product launches and claimed it could mitigate the impact of shifting tax policy through safe harbor arrangements and deeper engagement with TPO partners.
Behind those assurances, the complaint alleges a different picture. Investors claim Enphase overstated its ability to manage inventory levels and overstated how effectively it could cushion demand ahead of the 25D credit’s accelerated expiration. When the truth emerged, it became clear that a substantial portion of reported revenue had been pulled forward through safe harbor sales, obscuring underlying weakness.
The alleged misconduct begins on April 22, 2025, when Enphase filed its Form 10-Q for the first quarter and held an earnings call emphasizing inventory discipline and growth vectors. Similar messaging continued through the second quarter, including revenue guidance of $330 million to $370 million for Q3 2025 and repeated statements that inventory remained under control.
In July 2025, the federal government enacted legislation accelerating the termination of the 25D tax credit to December 31, 2025. Enphase executives publicly downplayed the risk, stating that demand would be pulled forward and that partnerships with TPOs would prevent market erosion.
The narrative broke on October 28, 2025. Enphase disclosed third-quarter results showing $410.4 million in revenue, of which $70.9 million consisted of safe harbor revenue pulled forward from future periods. Management simultaneously warned that elevated inventory would force reduced shipments and that the expiration of the 25D credit would weigh heavily on early-2026 revenue. The next day, ENPH shares fell $5.56, or 15.15%, closing at $31.14.
The stock drop on October 29, 2025 marked the primary corrective disclosure alleged in the complaint. Investors contend that the decline directly reflected the market’s reassessment of Enphase’s true demand profile and inventory position.
Analysts reacted swiftly. Evercore ISI cut its price target by 17.5%, warning against expectations of a rapid rebound. BMO Capital Markets reduced its target by 15.5%, emphasizing that Enphase’s Q3 revenue beat was driven largely by safe harbor sales. Goldman Sachs likewise lowered its target, citing Q4 guidance well below consensus and sharply reduced expectations for Q1 2026 revenue.
According to the complaint, these disclosures causes significant losses to shareholders who purchased ENPH during the class period.
The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Defendants include Enphase Energy, Inc., President and CEO Badrinarayanan Kothandaraman, and CFO Mandy Yang.
Plaintiffs allege scienter based on management’s repeated and specific assurances regarding inventory discipline and mitigation strategies, despite contrary internal realities. The complaint emphasizes executives’ direct involvement in earnings calls, guidance decisions, and communications with TPO partners.
The case is in its early stages, with plaintiffs seeking class certification, damages, and other relief on behalf of investors who acquired ENPH securities between April 22, 2025 and October 28, 2025.
The October 2025 disclosures triggered a sharp pivot in investor confidence, moving from cautious optimism to broader skepticism. External coverage emphasized that the market focused less on the quarterly “beat” and more on declining shipment expectations, inventory destocking, and a softer outlook for early 2026. Retail-investor discussion on platforms such as Reddit reflected similar concerns about demand trends and the sustainability of recent revenue levels, with many users questioning the extent to which safe harbor transactions contributed to reported results.
Across these forums, discussion frequently centered on whether the company’s near-term performance reflected underlying demand or timing-related factors tied to policy incentives such as the Section 25D tax credit. Some participants characterized the expected slowdown as a temporary, policy-driven headwind, while others expressed concern that inventory levels and reduced shipment guidance pointed to more sustained weakness. Overall, sentiment appeared mixed but more cautious, with increased scrutiny on revenue composition and forward guidance rather than a uniform consensus view.
Investors on Reddit’s r/stocks community pointed to the 15% overnight drop as evidence that the company’s "inventory discipline" was a facade, with many expressing frustration that demand was artificially inflated to mask a cyclical downturn.
Long-term holders on r/ValueInvesting questioned whether management's previous assurances were intentionally misleading, particularly regarding the sustainability of U.S. demand ahead of the tax credit expiration.
Wall Street's reaction was characterized by a swift and synchronized reduction in price targets as firms struggled to reconcile previous growth projections with the new reality of a revenue trough.
Analysts notably slashed their price target by 17.5% to $33, expressing weariness toward any "hockey-stick" recovery in late 2026. They cautioned that the Q3 beat was of low quality due to the high safe harbor component.
BMO Capital Markets downgraded the stock to "Underperform" and reduced its target to $31, emphasizing that organic revenue (excluding safe harbor) actually fell 8% below the company's own guidance range.
Goldman Sachs analysts lowered their target to $29, noting that Q4 guidance was meaningfully below consensus. They cited structural concerns regarding the 25D tax credit expiration as a headwind that would likely keep the stock under pressure through the first half of 2026.
The Motley Fool market analysis attributed the crash to the fact that Enphase "ruined one great quarter by warning of a worse one," specifically highlighting the steep drop in projected gross margins for the coming months.
Enphase’s SEC filings during the class period discussed exposure to policy changes and market cyclicality. However, investors allege these disclosures failed to adequately convey the magnitude of inventory risk and the extent to which revenue depended on accelerated safe harbor transactions.
The October 2025 Form 10-Q marked a turning point, revealing both the scale of safe harbor revenue and management’s decision to reduce shipments to destock inventory. Plaintiffs argue these admissions contradicted earlier representations and exposed risks that should have been disclosed sooner.
The Enphase lawsuit underscores how sensitive clean-energy companies can be to policy shifts, inventory management, and revenue timing. For investors, the case highlights the importance of scrutinizing guidance quality, reliance on non-recurring revenue sources, and the consistency of management messaging over time.
As the litigation unfolds, the outcome may carry broader implications for solar and energy-storage companies navigating tax-credit transitions and channel-inventory pressures. For now, shareholders are left to assess whether Enphase’s public narrative matched its internal realities—and whether the law will provide a remedy.
Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.
![Regenxbio, Inc. [RGNX] Securities Class Action Lawsuit Update](https://media.suewallst.com/cms-dev/Regenx_Bio_Inc_b1c83aa28b.png)
REGENXBIO, Inc. (RGNX) Securities Class Action Lawsuit: Investors Allege Gene Therapy Safety Risks Were Concealed

Ultragenyx (RARE) Investors Allege Misleading Assurances Behind Failed Phase III Trials

Kyndryl Holdings (KD) Securities Class Action: Internal Controls, Cash Flow Reporting, and a 55% Stock Collapse